GPT and Hepatic steatosis: Both EMO monotherapy and its combination with RSG significantly ameliorated liver steatosis and renal dysfunction compared with RSG-treated groups, as shown by reduced serum markers of liver damage (ALT, AST) and renal impairment (CREA, UN), decreased hepatic lipid content, and improved liver weight parameters (Figure S1).